Novartis and ProFound Therapeutics have entered into a four-year partnership aimed at discovering and developing new ...

Novartis is penning a four-year pact with ProFound Therapeutics to create new therapeutics for heart disease, with $750 ...

Using the ProFoundry platform and Novartis' expertise, the partners will identify novel proteins and drug targets for cardiovascular disease.

Cambridge, USA-based ProFound Therapeutics today announced a four-year collaboration with Swiss pharma giant Novartis to ...

ProFound Therapeutics enters multi-year strategic collaboration with Novartis to discover and develop novel therapeutics for cardiovascular disease: Cambridge, Massachusetts Frida ...

But Novartis stock climbed 1.4% to close at 112.26 as Travere stock fell 7.7%, closing at 16.56. Novartis Stock: A Long History Behind Atrasentan.

Novartis AG has agreed to buy U.S. biotech firm Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 billion. The Swiss company will pay $7 a share in cash up-front through a ...

Novartis' free cash flow increased by an impressive 5.7% in 2024, reaching $13.8 billion against $13.1 billion a year earlier. FCF even exceeded its net profit ($11.9 billion).

FRANKFURT (Reuters) -Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an ...

European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S. investment. The $200 billion pharma company intends to invest ...

Novartis has also been examining Lutathera for other indications. In September, it released Phase 2 data on Lutathera improving progression-free survival in patients with meningioma brain tumors. The ...